ß-Carotene bioaccessibility from biofortified maize (Zea mays) is related to its density and is negatively influenced by lutein and zeaxanthin.

Biofortification of maize with provitamin A (pro-VA) carotenoids has been successful, but the bioavailability of carotenoids needs to be explored. In the present study, we investigated the carotenoid content, micellarization and intestinal cell uptake of carotenoids from 10 maize hybrids [normal maize, quality protein maize (QPM), pro-VA carotenoid and double biofortified QPM + pro-VA maize hybrids] using a simulated in vitro digestion/Caco-2 cell model. The pro-VA carotenoid content of biofortified maize hybrids is 2-10 fold higher compared to that of normal maize. Furthermore, the ratio of non-pro-VA carotenoids lutein (LUT) plus zeaxanthin (ZEA) to the sum of pro-VA carotenoids ß-cryptoxanthin (BCX), α-carotene (AC) and ß-carotene (BC) in biofortified maize was much lower compared to that of normal maize. The consumption of 200 g day-1 of biofortified Pusa-PV-16-3 (BC = 808.4 µg per 100 g; AC = 839.3 µg per 100 g; BCX = 59 µg per 100 g) and Pusa-APQH8 (BC = 345.9 µg per 100 g; AC = 1739 µg per 100 g; BCX = 644.2 µg per 100 g) maize would contribute to 52 and 64% of RDAs for adult Indian men, respectively, after adjusting for cooking losses and conversion factors. The mean efficiency of micellarization of LUT (62.2% ± 5.3), ZEA (65% ± 4.7), and BCX (54% ± 9.5) exceeded that of AC (43% ± 8.9) and BC (49.8% ± 7.8) from all the maize hybrids. Furthermore, the micellarization and uptake in Caco-2 cells during a 4 h incubation period showed high correlation (P < 0.05) with the concentration of carotenoids in the maize digesta and micellar fraction, respectively. However, the LUT + ZEA content in the maize digesta and micellar fraction was inversely (p < 0.05) related to the BC micellarization and intestinal cell uptake, respectively. These results together suggest that the enrichment of pro-VA carotenoids together with decreasing the oxygenated carotenoid metabolites such as LUT and ZEA will further improve the bioavailability of BC from maize hybrids.

Validation of therapeutic anti-inflammatory potential of Arjuna Ksheera Paka - A traditional Ayurvedic formulation of Terminalia arjuna.

Arjuna Ksheera Paka (AKP), a traditional Ayurvedic formulation of Terminalia arjuna (T. arjuna) bark powder is used for its cardioprotective effects. However, its anti-inflammatory efficacy remained unexplored. In the present study, AKP was prepared in cow milk (as per standard Ayurvedic procedure) and compared with standard hydroalcoholic extract (HA) of T. arjuna. The extracts were analyzed for gross phytoconstituents levels, and their antioxidant activity was assayed by DPPH free radical scavenging activity and inhibition of lipid peroxidation. The in vivo anti-inflammatory activity of AKP and HA was studied in carrageenan-induced hind paw biphasic edema in C57BL/6 mice (at 200, 400 and 800 mg/kg BW). The percentage extraction yield of AKP was two folds higher than HA implying that the phytoconstituents in AKP were diluted by a factor of 0.5. The total polyphenol content of HA was (3.8 times) higher than AKP and the antioxidant activity of HA was also higher compared to AKP. Both the extracts, however, showed significant (p < 0.05) anti-inflammatory activity in reducing paw edema in mice. The efficacy of HA was more than AKP at early phase of inflammation, whereas, in the late phase of inflammation AKP was more efficacious and equipotent to HA. Thus, regardless of low in vitro antioxidant activity, AKP exhibited potential in vivo anti-inflammatory activity. The higher efficacy of AKP could be due to the presence of milk solids. These milk solids may act as adjuvants to T. arjuna's phytoconstituents, contributing to their sustained bioavailability, leading to higher in vivo anti-inflammatory efficacy at lower drug concentrations.